There's an old piece of medieval folklore that warned: "Woe to the child who tastes salty from a kiss on the brow, for he is cursed and soon will die." For centuries, no one knew exactly what that referred to. We now know it was almost certainly describing children with cystic fibrosis. For most of human history, that diagnosis was a death sentence. But thanks to a drug called Trikafta, that reality has been flipped upside down — for most patients. Understanding how Trikafta works for cystic fibrosis is the key to understanding one of the most dramatic medical breakthroughs of the 21st century.

How Does Trikafta Actually Work?

Trikafta is a triple-combination drug approved in 2019 that targets the root molecular cause of cystic fibrosis. It combines three medications — elexacaftor, tezacaftor, and ivacaftor — each of which attacks the problem from a different angle.

To understand how they work together, you need to know what's broken. Cystic fibrosis is caused by mutations in the CFTR gene, which produces a protein that acts as a gateway for salt ions moving in and out of your cells. When CFTR doesn't work properly, salt leaks out of cells uncontrolled — hence the salty-tasting skin. The most common mutation, called F508del, causes the resulting CFTR protein to be misfolded. A misfolded protein is unstable, breaks down quickly, and rarely makes it to the cell surface where it's needed.

That's where Trikafta steps in with a three-pronged fix:

  • Elexacaftor and tezacaftor are "correctors." They each bind to a different spot on the misfolded CFTR protein and help it fold into the right shape, making it stable enough to survive long enough to do its job.
  • Ivacaftor is a "potentiator." Once the corrected protein reaches the cell surface, ivacaftor acts like a key that unlocks the ion channel, allowing salt to flow through the way it should.

Think of it this way: imagine CFTR is a gate that's supposed to open and close to manage salt flow. The F508del mutation means the gate is crumpled before it even gets installed. Elexacaftor and tezacaftor straighten out the gate. Ivacaftor makes sure it can actually open. Together, they restore something close to normal function.

The results have been nothing short of extraordinary. Within 24 hours of their first dose, many patients experience what the cystic fibrosis community calls "the Purge" — a massive clearing of the thick, tar-like mucus that has been clogging their lungs. Some patients reported being able to run up hills when they previously couldn't walk up stairs. Others began training for marathons. Some were even able to get pregnant for the first time, since CFTR function was restored throughout the entire body, including the cervix.

What Is Cystic Fibrosis and What Causes It?

Cystic fibrosis is a hereditary disease caused by mutations in a single gene — the CFTR gene (cystic fibrosis transmembrane conductance regulator), identified in 1989. It affects the body's ability to regulate salt and water levels in epithelial cells — the cells lining your lungs, digestive system, reproductive organs, and more.

The disease got its name in the 1930s, when pathologists found fibrous cysts in the pancreas samples of sick children. But while the pancreas was where it was first spotted, cystic fibrosis causes problems almost everywhere. When CFTR proteins malfunction, the body can't hold onto the salt it needs, and the mucus that lines our organs becomes dangerously thick and sticky.

What Does Cystic Fibrosis Do to the Body?

Healthy mucus is thin and watery — it traps bacteria, dust, and pathogens, and then gets swept away. In cystic fibrosis, that mucus turns thick and tar-like, clogging the very systems it's supposed to protect.

  • Lungs: Thick mucus traps infectious bacteria, leading to chronic, severe lung infections. Because these infections are highly contagious to other CF patients, people with cystic fibrosis have been practicing social distancing long before COVID made it a household term.
  • Pancreas: Mucus blocks digestive enzymes from reaching the small intestine, causing malabsorption. Patients often need to take enzyme supplements with every meal.
  • Reproductive system: Mucus in the cervix and other reproductive tissues can make pregnancy difficult or impossible without treatment.

One of the oldest and most grueling traditional treatments is manual percussion therapy — literally having someone pound on your chest multiple times a day to try to knock mucus loose from the lungs. It works, but it's exhausting, time-consuming, and has to be done every single day.

What Is the CFTR Gene and Why Does It Matter?

The CFTR gene is the single point of failure in cystic fibrosis — but it's a complicated one. Scientists have identified more than 1,200 different mutations in the CFTR gene that can cause disease, and not all of them cause the same kind of problem.

Some mutations produce shortened, non-functional versions of the protein. Others affect how the protein folds. Still others produce a protein that gets to the right place but simply doesn't open the way it should. The most common mutation — F508del, present in about 85% of US cystic fibrosis patients — causes a single amino acid to be missing, which cascades into massive structural problems for the resulting protein.

This diversity of mutations is exactly what makes treating cystic fibrosis so complicated, and why a drug like Trikafta, while revolutionary, can't fix every case.

Why Can't Everyone with CF Take Trikafta?

Trikafta was designed primarily around the F508del mutation, and it works brilliantly for that. More recent research has shown it can also benefit patients with some other mutations — bringing the total of eligible patients to around 90%. But that leaves roughly 10% of cystic fibrosis patients — tens of thousands of people worldwide — for whom Trikafta simply doesn't work.

This gap is even more pronounced globally. F508del is most common in North America and Western Europe. In other populations, different CFTR mutations dominate, making Trikafta far less useful in those regions.

There are also real barriers for patients who technically could benefit:

  • Cost: In the US, Trikafta costs over $300,000 per year before insurance, though it costs about $6,000 to manufacture. Generic versions exist in some countries for around $12,000 — still out of reach for many.
  • Side effects: Some patients experience cataracts, liver problems, insomnia, and other neurological issues serious enough to stop treatment.

Vertex Pharmaceuticals has released a follow-up drug called Alyftrek, a once-daily combination that targets similar mutations but may help an even broader range of patients than Trikafta. But for the 10% left behind, a fundamentally different approach is needed.

Is There a Cure for Cystic Fibrosis Yet?

Trikafta isn't a true cure — patients must take it twice daily indefinitely to remain healthy. Stop taking it and the thick mucus comes back. Before Trikafta, few cystic fibrosis patients lived past their 40s. Now, doctors estimate that patients who stay on Trikafta can expect a normal life expectancy. The disease has transformed so dramatically that children with cystic fibrosis no longer automatically qualify for the Make-A-Wish Foundation — their cases now need individual review.

It's a shift comparable to the HIV/AIDS turning point in the 1990s, when new antiretroviral drugs turned a terminal diagnosis into a manageable chronic condition. Doctors suddenly had to learn how to care for CF patients who were going to live — and patients had to grapple with the unexpected reality that they needed a retirement plan.

What Does the Future of CF Gene Therapy Look Like?

For the 10% that Trikafta and Alyftrek can't help, scientists are working on more fundamental solutions — ones that don't just manage the broken protein, but fix or replace the broken gene itself.

  • CRISPR gene editing: In 2024, researchers successfully used CRISPR to correct a CFTR mutation in mice, restoring the ability to produce full-length, functional CFTR proteins. The downside: each mutation requires a bespoke solution, making it difficult to scale across more than 1,000 known mutations.
  • Gene addition therapy: Rather than editing the broken gene, scientists are exploring adding a brand-new, fully-functional CFTR gene to cells. It doesn't matter what broken version already exists — the cells just also get a working copy. This approach is still in the cells-in-a-dish stage, but it could sidestep the personalization problem entirely.

The story of cystic fibrosis is a remarkable one — from a medieval curse, to a terminal diagnosis, to a condition that millions now manage well enough to run marathons and raise families. The science isn't finished yet. But for the first time in history, a full cure feels like a genuine possibility, not just a hope.